EDISON EQUITY RESEARCH: SQI DIAGNOSTICS
30 September 2015 - 1:12AM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH:SQI DIAGNOSTICS - TAPPING INTO
CONSIDERABLE MARKET OPPORTUNITIES
SQI has made steady progress over recent months in signing new
agreements with drug development companies in its high-volume assay
business. Encouragingly, service revenues are now booked for
custom-made tests early on in development, albeit at modest levels.
While the conversion of customers from early contract
work/validation to meaningful revenue-generating accounts is slower
than expected, industry interest continues to grow steadily for
SQI’s multiplexing technology capabilities, as does its pipeline of
potential customers.
SQI Diagnostics is a Canadian diagnostics company. It develops and
sells multiplexed research diagnostics to pharmaceutical companies
to support clinical research and in vitro diagnostics tests to
centralised diagnostics labs for diagnosing autoimmune
diseases.
To view our full report, please click here
Click here to view all of Edison Investment
Research’s published reports
Merrill Lynch (NYSE:SQD)
Historical Stock Chart
From May 2024 to Jun 2024
Merrill Lynch (NYSE:SQD)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Merrill Lynch (New York Stock Exchange): 0 recent articles
More Merrill Lynch News Articles